Allogene Therapeutics, Inc., a clinical-stage biotechnology company, has announced the publication of two significant abstracts ahead of the 2025 ASCO Annual Meeting. The first abstract highlights an oral presentation on ALLO-316, an investigational AlloCAR T product targeting CD70, which is being studied in patients with advanced or metastatic renal cell carcinoma. The presentation will discuss updated data from the Phase 1 TRAVERSE study, focusing on the Phase 1b expansion cohort where patients received a regimen of cyclophosphamide and fludarabine followed by a dose of 80 million CAR T cells. Additionally, the company will present a Trial-in-Progress poster on the Phase 2 ALPHA3 trial, which explores cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation strategy for patients with large B-cell lymphoma who remain minimal residual disease positive after initial chemoimmunotherapy. These findings underscore Allogene's pioneering efforts in developing allogeneic CAR T products for cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.